Merck (NYSE:MRK), one of the most recognizable names in the pharmaceutical industry, is devoted to the development of new drugs that can treat a wide range of afflictions, from diabetes to cancer.

So why is it collaborating with technology giant Samsung?

Well, it's not quite what you think. Today, Merck announced a partnership with Samsung Bioepis, a joint venture between Samsung's biologics unit and biotech company Biogen Idec. In this video, health-care analyst Max Macaluso discusses the detai mls of this deal and how it fits into Merck's total business.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.